ArticleGut2020
Gut mycobiome of primary sclerosing cholangitis patients is characterised by an increase of
Article in Gut, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gut Mycobiome in Inflammatory Bowel Disease: A Systematic Review of Case-Control Studies.Inflammatory bowel diseases · 2025Pooled it
- Compositional and functional differences of gut microbiome and metabolome inform pathogenesis of cholestatic liver disease.Gut microbes · 2026Article
- The role and possible mechanism of intestinal fungi in the progression of chronic liver diseases.NPJ biofilms and microbiomes · 2026Review
- Research progress on the role of gut microbiota dysbiosis in the pathogenesis of immune-mediated liver diseases.Frontiers in immunology · 2026Review
- Microbial Modulation of the Gut-Liver Axis in Autoimmune Liver Diseases.Seminars in liver disease · 2025Review
- Gut-Liver Axis, Microbiota, Bile Acids, and Immune Response in Pathogenesis of Primary Sclerosing Cholangitis: An Overview.Journal of clinical medicine · 2025Review
- Microbial Landscapes of the Gut-Biliary Axis: Implications for Benign and Malignant Biliary Tract Diseases.Microorganisms · 2025Review
- Impact of Gut Microbiome on Gut Permeability in Liver and Gut Diseases.Microorganisms · 2025Review
- Article
- Unique clinical, morphological, and molecular characteristics of tumors associated with PSC-IBD.Virchows Archiv : an international journal of pathology · 2025Review
- Gut microbiome and liver diseases.Fundamental research · 2025Review
- Gut mycobiome alterations and implications for liver diseases.PLoS pathogens · 2024Review
- Characterization of the Gut Microbiota and Mycobiota in Italian Pediatric Patients With Primary Sclerosing Cholangitis and Ulcerative Colitis.Inflammatory bowel diseases · 2024Article
- Fecal Mycobiota in Patients with Inflammatory Bowel Diseases and Extraintestinal Manifestations.Gut microbes reports · 2024Article
- Metagenome-based characterization of the gut bacteriome, mycobiome, and virome in patients with chronic hepatitis B-related liver fibrosis.Frontiers in microbiology · 2024Article
- Candida spp. in Human Intestinal Health and Disease: More than a Gut Feeling.Mycopathologia · 2023Review
- Fungal infections and the fungal microbiome in hepatobiliary disorders.Journal of hepatology · 2023Review
- The microbiota and the gut-liver axis in primary sclerosing cholangitis.Nature reviews. Gastroenterology & hepatology · 2023Review
- Article
- Alterations of bacteriome, mycobiome and metabolome characteristics in PCOS patients with normal/overweight individuals.Journal of ovarian research · 2022Article
Corrections and comments
- Comment on
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.